|Slideshows|July 4, 2017

Real-World Effectiveness of Antipsychotics

Which of these agents best prevents relapse? A recent study employed a novel approach to find out.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Reframing the Side Effect: Walter Brown, MD, on Placebo and Nocebo

ByJoseph F. Goldberg, MD,Walter A. Brown, MD

July 31st 2026

This Month In Alzheimer Disease: July’s Pharmacology and Research Developments

ByJessica Walters

July 31st 2026

Expectation, Alliance, and Outcome: Rethinking Placebo in Psychiatric Practice

ByJoseph F. Goldberg, MD,Walter A. Brown, MD

July 31st 2026

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

ByGustavo Alva, MD, DFAPA

July 31st 2026

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval

ByJessica Walters,Raman Baweja, MD

July 31st 2026

Latest CME

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Real-World Effectiveness of Antipsychotics

Related Content

Reframing the Side Effect: Walter Brown, MD, on Placebo and Nocebo

This Month In Alzheimer Disease: July’s Pharmacology and Research Developments

Expectation, Alliance, and Outcome: Rethinking Placebo in Psychiatric Practice

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

A Preventive Window In Post-TBI Care and Subsequent Alzheimer Pathology

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval